Oragenics Enlists Regulatory Expert for Concussion Therapy Advance
Event summary
- Oragenics has engaged DUCK FLATS Pharma to support FDA IND readiness and clinical trial design for its ONP-002 concussion therapy.
- DUCK FLATS Pharma has been involved in the development and approval of approximately 40 drug programs, including intranasal therapies like Narcan® and neffy®.
- The collaboration aims to align Oragenics’ Phase 2a clinical trial in Australia with its U.S. regulatory strategy.
- The global concussion market is projected to reach over $9 billion by 2027, and the nasal drug delivery market is expected to reach $125+ billion by 2030.
- ONP-002 is currently in Phase 2a clinical trials in Australia, with U.S. Phase IIb trials planned.
The big picture
Oragenics’ partnership with DUCK FLATS Pharma highlights the increasing complexity and cost of drug development, particularly for neurological therapies. The collaboration underscores the strategic importance of regulatory expertise in securing FDA approval and accelerating market access. The company is attempting to capitalize on a large, underserved market—concussions—but faces significant competition from other potential therapies and delivery methods.
What we're watching
- Regulatory Risk
- The success of ONP-002 hinges on navigating FDA approval, and DUCK FLATS Pharma’s experience will be critical, but their past successes don’t guarantee a smooth path.
- Clinical Execution
- The alignment of Australian and U.S. clinical trials will be a key indicator of Oragenics’ ability to manage a complex, global development program.
- Market Adoption
- While the concussion market is substantial, the lack of existing therapies doesn’t guarantee rapid adoption of ONP-002 if approved; physician and patient acceptance will be vital.
Related topics